MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Bladder and Urothelial Cancer Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,070 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,070 works in the cohort · of 4,299,418page 30 of 62

Labels cover 8 of 3,070 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,070 of 3,070 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundno abstractunlabeled
Development and International Evaluation of an Artificial Intelligence–based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non–muscle-invasive Bladder Cancer
Jethro C.C. Kwong, Zizo Al‐Daqqaq, Yashan Chelliahpillai, Soomin Lee, Kellie Kim, Maximiliano Ringa +23 more
2025· article· en· European Urology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affno abstractunlabeled
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer
Kamaneh Montazeri, George Dranitsaris, Jonathan Thomas, Catherine Curran, MA. Preston, GS. Steele +6 more
2021· article· en· Urologic Oncology Seminars and Original Investigations· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.
Terence W. Friedlander, Matthew I. Milowsky, Peter H. O’Donnell, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig +11 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
aboutno affunlabeled
Bladder Cancer Patient Advocacy: A Global Perspective
Diane Zipursky Quale, Rick Bangs, Monica Smith, David Guttman, Tammy Northam, Andrew Winterbottom +3 more
2015· review· en· Bladder Cancer· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affno abstractunlabeled
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial
John J. Coen, Joseph P. Rodgers, Philip J. Saylor, Cheryl T. Lee, Chin‐Lee Wu, William A. Parker +9 more
2024· article· en· International Journal of Radiation Oncology*Biology*Physics· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Immuno-Oncology Advances in Genitourinary Cancers
Peter D. Zang, Arkhjamil Angeles, Tanya B. Dorff, Sumanta K. Pal, Shilpa Gupta
2024· article· en· American Society of Clinical Oncology Educational Book· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affvenueunlabeled
Urinary-Based Markers for Bladder Cancer Detection
Tilman Todenhöfer, Michele Lodde, Kim van Kessel, Renate Pichler, Antonia Vlahou, Yair Lotan
2020· article· en· Société Internationale d’Urologie Journal· Medicine
machine prediction:candidate · noneconsensus · none
6
citations

How this was built: Screen · Findings · About